CNS Drugs

, Volume 19, Issue 3, pp 265–272 | Cite as


As Adjunctive Treatment of Partial Seizures
  • Greg Warner
  • David P. Figgitt
Adis Drug Profile


▴ Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel ζ2-δ proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmitter release caused by binding to the α2-δ protein, resulting in allosteric modulation of P/ Q-type voltage-gated calcium channels.

▴ In three well designed trials, oral pregabalin as adjunctive therapy in patients with refractory partial seizures was significantly (p ≤ 0.0007) more effective than placebo in reducing seizure frequency when administered at dosages of 150–600 mg/day (as two or three divided doses).

▴ Adjunctive pregabalin produced an overall mean 41.3% improvement from baseline in 28-day seizure-free rate in four long-term (maximum exposure 1764 days), open-1abel studies in 1480 patients.

▴ CNS-related effects (e.g. dizziness and somnolence) were the most frequent dose-related treatment-emergent adverse events associated with adjunctive pregabalin therapy.


Pregabalin Alprazolam Partial Seizure Seizure Frequency Diabetic Peripheral Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hovinga CA. Novel anticonvulsant medications in development. Expert Opin Investig Drags 2002 Oct; 11(10): 1387–406CrossRefGoogle Scholar
  2. 2.
    Walker MC, Sander JW. New anti-epileptic drugs. Expert Opin Invest Drags 1999; 8(10): 1497–510CrossRefGoogle Scholar
  3. 3.
    Ben-Menachem E, Henriksen O, Johannessen SI. Diagnosis and treatment of partial seizures. CNS Drugs 1999 Jan; 11(1): 23–39CrossRefGoogle Scholar
  4. 4.
    Ashton H, Young AH. GABA-ergic drags: exit stage left, enter stage right. J Psychopharmacol (Oxf) 2003; 17(2): 174–8CrossRefGoogle Scholar
  5. 5.
    Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drags. In pressGoogle Scholar
  6. 6.
    Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drags 2004; 64(24): 2813–20CrossRefGoogle Scholar
  7. 7.
    Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005; 65(1): 111–8PubMedCrossRefGoogle Scholar
  8. 8.
    McClelland D, Evans RM, Barkworth L, et al. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC Pharmacol 2004 Aug 4; 4 (14) [online]. Available from URL: [Accessed 2005 Feb 3]
  9. 9.
    Willmore LJ. Clinical pharmacology of new antiepileptic drugs. Neurology 2000; 55(11 Suppl. 3): S17–24PubMedGoogle Scholar
  10. 10.
    Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drags: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001; 43(1): 11–58PubMedCrossRefGoogle Scholar
  11. 11.
    Dooley DJ, Donovan CM, Meder WP, et al. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K[su+-evoked [3H]- norepinephrine release from rat neocortical slices.Synapse 2002 Sep 1; 45(3): 171–90PubMedCrossRefGoogle Scholar
  12. 12.
    Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002 Feb; 42(2): 229–36PubMedCrossRefGoogle Scholar
  13. 13.
    Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000 Dec; 295(3): 1086–93PubMedGoogle Scholar
  14. 14.
    Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000 Feb 18; 280(2): 107–10PubMedCrossRefGoogle Scholar
  15. 15.
    Taylor CP, Vartanian MG. Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models [abstract no. 1.109]. Epilepsia 1997; 38Suppl. 8: 35Google Scholar
  16. 16.
    Hindmarch I, Dawson J, Stanley N. Evaluation of cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers [abstract no. NR206 plus poster]. American Psychiatric Association 2002 Annual Meeting: New Research Abstracts; 2002 May 18–23; Philadelphia, 56Google Scholar
  17. 17.
    Hindmarch I, Dawson J, Stanley N. Evaluation of the sleep activity profile of pregabalin compared to alprazolam in normal volunteers [abstract no. NR415 plus poster]. American Psychiatric Association 2002 Annual Meeting: New Research Abstracts; 2002 May 18–23; Philadelphia, 112Google Scholar
  18. 18.
    Morrell M, Brigell M, Chartier K, et al. A double-blind, placebo-controlled, parallel-group study to assess the effects of pregabalin on reproductive function in healthy males [abstract no. P04.096]. Neurology 2004; 62Suppl. 5: A314Google Scholar
  19. 19.
    Busch JA, Strand JC, Posvar EL, et al. Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses [abstract no. 2.108]. Epilepsia 1998; 39Suppl. 6: 58Google Scholar
  20. 20.
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45Suppl. 6: 13–8PubMedCrossRefGoogle Scholar
  21. 21.
    Bockbrader HN, Wesche D. Pharmacokinetic profile of pregabalin: results of a series of studies [abstract no. NR378]. American Psychiatric Association 2004 Annual Meeting: New Research Abstracts; 2004 May 1–6; New York, 140-1Google Scholar
  22. 22.
    Corrigan BW, Pool WF, Posvar EL, et al. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin Pharmacol Ther 2001 Feb; 69(2): 18Google Scholar
  23. 23.
    Bockbrader HN, Hunt T, Strand J, et al. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies [abstract no. P06.051]. Neurology 2000 Apr 11; 54Suppl. 3: A421Google Scholar
  24. 24.
    Corrigan B, Bockbrader H, Burger P, et al. Pregabalin population pharmacokinetics in patients with refractory partial seizures [abstract no. P452]. Epilepsia 2002; 43Suppl. 8: 144–5Google Scholar
  25. 25.
    Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003 Mar; 43(3): 277–83PubMedCrossRefGoogle Scholar
  26. 26.
    Bockbrader H, Burger P, Kugler A, et al. The oral clearance (CL/F) of commonly prescribed antiepileptic drugs (AEDs) is unaffected by concomitant administration of pregabalin in adult patients with refractory partial seizures [abstract no. P453]. Epilepsia 2002; 43Suppl. 8: 145Google Scholar
  27. 27.
    Bockbrader HN, Posvar EL, Hunt T, et al. Pregabalin does not alter the effectiveness of an oral contraceptive [abstract no. P04.097]. Neurology 2004; 62Suppl. 5: A314Google Scholar
  28. 28.
    French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003 May 27; 60(10): 1631–7PubMedCrossRefGoogle Scholar
  29. 29.
    Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45(1): 20–7PubMedCrossRefGoogle Scholar
  30. 30.
    Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005; 64(3): 475–80PubMedCrossRefGoogle Scholar
  31. 31.
    Miller R, Frame B, Corrigan B, et al. Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin Pharmacol Ther 2003 Jun; 73(6): 491–505PubMedCrossRefGoogle Scholar
  32. 32.
    Guberman A, Anhut H, Lee C, et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible and fixed dosing [abstract no. P04.095]. Neurology 2004; 62Suppl. 5: 313–4Google Scholar
  33. 33.
    Spiegel K, Baulac M, Lee CM, et al. Long-term seizure freedom in patients with partial seizures treated with add-on pregabalin: an analysis of four, long-term, open-1abel trials [abstract no. P04.098]. Neurology 2004; 62Suppl. 5: 314–5Google Scholar
  34. 34.
    Greiner MJ, Lee CM, Knapp LE, et al. Pregabalin shows efficacy in reducing simple partial, complex partial, and secondarily generalized seizures [abstract no. P04.099]. Neurology 2004; 62Suppl. 5: 315Google Scholar
  35. 35.
    Huppertz H-J, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42(6): 790–2PubMedCrossRefGoogle Scholar
  36. 36.
    Asconape JJ, Hartman LM, Salanova V, et al. Pregabalin-associated myoclonus [abstract no. 2.238]. Epilepsia 1999; 40Suppl. 7: 143Google Scholar
  37. 37.
    Pfizer. Lyrica® summary of product characteristics [online]. Available from URL: [Accessed 2005 Jan 10]
  38. 38.
    New seizure medicine may be approved soon [online]. Available from URL: [Accessed 2004 Jun 23]
  39. 39.
    Pfizer Inc. Pfizer statement on regulatory status of Lyrica [online]. Available from URL: [Accessed 2004 Sep 9]
  40. 40.
    Pfizer Inc. FDA approves Pfizer’s Lyrica™ for the treatment of the two most common forms of neuropathic (nerve) pain [online]. Available from URL: [Accessed 2004 Dec 31]

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Greg Warner
    • 1
  • David P. Figgitt
    • 1
  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations